Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics, a NASDAQ-listed medical device and healthcare services company focusing on sleep-related breathing disorders, reported a 70% year-over-year revenue increase in Q1 2026 driven by its acquisition of The Sleep Center of Nevada and a business model pivot. Gross profit grew 103%, and gross margin improved to 60%. Operating expenses r…